Updates from the Society for Integrative Oncology 2026 International Conference
At the Society for Integrative Oncology (SIO) 2026 International Conference, emerging research signaled an important shift in cancer care: acupuncture and electroacupuncture are no longer viewed simply as tools for symptom relief, but as therapies that may actively bolster physical function, resilience, and recovery throughout treatment.
Chemotherapy-induced peripheral neuropathy frequently persists for months or years, burdening survivors with chronic pain, burning, numbness, and tingling. In a Dana-Farber Cancer Institute randomized trial, electroacupuncture significantly outperformed usual care, improving neuropathy-specific quality-of-life scores by 8.7 points compared to 1.2 points after eight weeks. To translate these gains into targeted care, an expanded trial of 255 cancer survivors is currently mapping nerve and pain responses to determine precisely who benefits most and why.
Equally compelling is how acupuncture may protect the body during active chemotherapy. In an analysis of 222 patients, electroacupuncture buffered against severe drops in neutrophils—a preservation linked to improved disease-free survival that was achieved without reducing chemotherapy dose intensity or completion rates. A complementary study of 237 patients confirmed similar neutrophil protection in vulnerable cohorts, alongside favorable immune cell alterations and encouraging survival outcomes. Together, these data suggest acupuncture could help the body better withstand the physiologic rigors of cytotoxic therapy.
The benefits extend across other common survivorship challenges. Research from Memorial Sloan Kettering Cancer Center and the University of Pennsylvania demonstrated clinically meaningful, sustained improvements in insomnia. Backing this, a review of 11 randomized trials across 994 patients and survivors showed marked improvements in subjective sleep, as well as secondary gains in depression and overall quality of life. Real-world clinical implementation reflects these findings: an evaluation of a hospital-based program encompassing 176 sessions across 27 patients recorded significant reductions in anxiety, nausea, insomnia, fatigue, pain, and paresthesia.
As leading cancer centers delve into the biological mechanisms—including immune signaling, metabolic shifts, and genetic profiles—the field is evolving toward true precision integrative oncology. The conversation is expanding beyond whether acupuncture can suppress an isolated side effect to a far more consequential question: how it can help patients stay stronger through treatment and recover more fully afterward.
References:
Society for Integrative Oncology. 2026 International Conference of the Society for Integrative Oncology: Cultivating Community and Belonging in Integrative Oncology. September 29-October 1, 2026; Detroit, MI.
Lu W, Giobbie-Hurder A, Freedman RA, et al. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer survivors: a randomized controlled pilot trial. Oncologist. 2020;25(4):310-318. doi:10.1634/theoncologist.2019-0489.
Baseline quantitative sensory testing (QST) characteristics in the ACT phase III randomized trial of electroacupuncture for chemotherapy-induced peripheral neuropathy. Presented at: Society for Integrative Oncology 2026 International Conference; September 29-October 1, 2026; Detroit, MI.
Electroacupuncture buffers chemotherapy-induced neutropenia to improve disease-free survival in gastric cancer: a post-hoc analysis of a randomized clinical trial. Presented at: Society for Integrative Oncology 2026 International Conference; September 29-October 1, 2026; Detroit, MI.
Electroacupuncture improves overall survival and ameliorates chemotherapy-induced neutropenia via systemic immune remodeling in gastric cancer: a post-hoc analysis of a randomized clinical trial identifying MDSCs as a predictive biomarker. Presented at: Society for Integrative Oncology 2026 International Conference; September 29-October 1, 2026; Detroit, MI.
Zhu YJ, Chang XS, Wu XY, et al. Electro-acupuncture for quality of life during adjuvant chemotherapy in gastric cancer: a randomized trial. J Natl Cancer Inst. 2026;118(4):603-612. doi:10.1093/jnci/djaf309.
Garland SN, Xie SX, DuHamel K, et al. Acupuncture versus cognitive behavioral therapy for insomnia in cancer survivors: a randomized clinical trial. J Natl Cancer Inst. 2019;111(12):1323-1331. doi:10.1093/jnci/djz050.
Acupuncture for insomnia and comorbid symptoms in cancer: a systematic review with meta-analysis. Presented at: Society for Integrative Oncology 2026 International Conference; September 29-October 1, 2026; Detroit, MI.
The integration of acupuncture into oncological care at IRCCS-ISMETT: a pilot program for oncology and transplant patients. Presented at: Society for Integrative Oncology 2026 International Conference; September 29-October 1, 2026; Detroit, MI.
STAT1 and NF-κB activity and CIPN symptom burden in breast cancer survivors: biomarker analysis of a randomized acupuncture trial. Presented at: Society for Integrative Oncology 2026 International Conference; September 29-October 1, 2026; Detroit, MI.
Toward precision insomnia care for cancer survivors: dopamine-related metabolomic insights from acupuncture versus CBT-I. Presented at: Society for Integrative Oncology 2026 International Conference; September 29-October 1, 2026; Detroit, MI.
Genovese TJ, Gehrman P, Yang M, et al. Genetic predictors of response to acupuncture or cognitive behavioral therapy for insomnia in cancer survivors: an exploratory analysis. J Pain Symptom Manage. 2021;62(3). doi:10.1016/j.jpainsymman.2021.03.002.
This website provides general information only. Content does not constitute medical advice. Consult a healthcare professional for medical guidance.